Abstract
BackgroundThe fatty liver index (FLI) is frequently used as a non-invasive clinical marker for research, prognostic and diagnostic purposes. It is also used to stratify individuals with hepatic steatosis such as non-alcoholic fatty liver disease (NAFLD), and to detect the presence of type 2 diabetes or cardiovascular disease. The FLI is calculated using a combination of anthropometric and blood biochemical variables; however, it reportedly excludes 8.5-16.7% of individuals with NAFLD. Moreover, the FLI cannot quantitatively predict liver fat, which might otherwise render an improved diagnosis and assessment of fatty liver, particularly in longitudinal studies. We propose FLI+ using predictive regression modelling, an improved index reflecting liver fat content that integrates 12 routinely-measured variables, including the original FLI.Methods and findingsWe evaluated FLI+ on a dataset from the UK Biobank containing 28,796 individual estimates of proton density fat fraction derived from magnetic resonance imaging across normal to severe levels and interpolated to align with the original FLI range. The results obtained for FLI+ outperform the original FLI by delivering a lower mean absolute error by approximately 47%, a lower standard deviation by approximately 20%, and an increased adjusted R2statistic by approximately 49%, reflecting a more accurate representation of liver fat content.ConclusionsOur proposed model predicting FLI+ has the potential to improve diagnosis and provide a more accurate stratification than FLI between absent, mild, moderate and severe levels of hepatic steatosis.
Publisher
Public Library of Science (PLoS)
Reference82 articles.
1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;European Association for the Study of The Liver and European Association for the Study of Diabetes (EASD) and others;Obesity Facts,2016
2. Alcoholic liver disease: Current insights into cellular mechanisms;L Petagine;World Journal of Biological Chemistry,2021
3. Screening for nonalcoholic fatty liver disease in the primary care clinic;V Pandyarajan;Gastroenterology & Hepatology,2019
4. Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD;P Zhang;Frontiers in Physiology,2021
5. Complications, morbidity and mortality of nonalcoholic fatty liver disease;A Mantovani;Metabolism,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献